AI Doctor offers an AI‑driven digital twin care platform that uses symptom chatbots, genomic analysis, and liquid‑biopsy testing to guide users to the right specialist, predict disease risk, and recommend optimal medications. The service includes a DNA‑based pharmacogenomics report covering over 210 drugs and a blood test that detects early cancer signals, all powered by analysis of more than 3 million medical cases.
Funding
Funding not disclosed
Founders
Product
Problem
Patients often struggle to identify the most appropriate medical specialist for their symptoms, leading to delayed care and unnecessary consultations. Additionally, individuals lack accessible tools to interpret their genomic data for disease risk, drug response, and early cancer detection.
Solution
AI Doctor provides an AI‑driven digital twin care platform that conversationally gathers symptom information and matches users to the correct specialist with 98.6 % accuracy, leveraging a database of over three million clinical cases. The platform also offers a genomic digital twin analytics service that generates a comprehensive health map from a single genome upload, covering risk assessment for 22 000 diseases and pharmacogenomic insights for more than 210 medications. A pharmacogenomics report (BestMed) identifies optimal drug choices and potential adverse reactions based on DNA. Additionally, the CancerTracer™ liquid‑biopsy test detects early cancer signals from a blood sample, enabling predictive monitoring without invasive procedures.
Target Audience
Primary users are consumers seeking personalized health guidance, as well as healthcare providers and tele‑medicine services that need AI‑assisted triage, genomic risk assessment, and early cancer detection tools.
Features
- AI chatbot trained on 3 M+ clinical cases that collects symptoms and instantly recommends the appropriate specialist
- Genomic digital twin analytics delivering disease risk profiles for 22 K conditions from one genome upload
- Pharmacogenomics (PGx) report covering 210+ drugs to guide medication selection and avoid side effects
- CancerTracer™ liquid‑biopsy test that identifies early cancer biomarkers in blood for proactive detection and treatment tracking
- Integrated platform that combines symptom triage, genomic risk mapping, drug response analysis, and early cancer screening in a single user interface